Glioblastoma multiforme (GBM) is the most common and aggressive primary brain tumour in adults. Treatments include surgical resection, radiotherapy, and chemotherapy. Despite this, the prognosis remains poor, with an impacted quality of life during treatment coupled with brain tumour recurrence; thus, new treatments are desperately needed. In this review, we focus on recent advances in G-protein-coupled receptor (GPCR) targets. To date, the most promising targets are the chemokine, cannabinoid, and dopamine receptors, but future work should further examine the melanocortin receptor-4 (MC4R), adhesion, lysophosphatidic acid (LPA) and smoothened (Smo) receptors to initiate new drug-screening strategies and targeted delivery of safe and effective GBM therapies.

多形性胶质母细胞瘤 (GBM) 是成人中最常见和最具侵袭性的原发性脑肿瘤。治疗包括手术切除、放疗和化疗。尽管如此，预后仍然很差，治疗期间的生活质量受到影响，并伴有脑肿瘤复发；因此，迫切需要新的治疗方法。在这篇综述中，我们关注 G 蛋白偶联受体 (GPCR) 靶标的最新进展。迄今为止，最有希望的靶点是趋化因子、大麻素和多巴胺受体，但未来的工作应进一步检查黑皮质素受体 4 (MC4R)、粘附、溶血磷脂酸 (LPA) 和平滑 (Smo) 受体，以启动新药-筛选策略和有针对性地提供安全有效的 GBM 疗法。